BioMérieux Shares Rebound 2.51% to €73.65 After a 7-Year Low
Shares of the Lyon-based in vitro diagnostics specialist are regaining ground this Tuesday, May 12, moving against the trend of a declining SBF 120, which is down 1.1%. The increase follows a very challenging quarterly period and an RSI that dropped below 20 at the end of April. However, the stock remains significantly below its moving averages.
A Marked Rebound in a Declining SBF 120
BioMérieux gains 2.51% to €73.65 during the session, marking the second largest increase in the SBF 120 behind SES (+3.68%). Meanwhile, the index itself is down by 1.1%, in a market climate that is generally bearish across European exchanges. The CAC 40 is down 1.03% at 7,973.59 points, and the DAX has fallen by 1.34%.
The rebound comes after a prolonged drop: the price is still down -20.76% over three months and -36.67% over a year, following the warning on April 23. On that day, the company had lowered its annual targets after reporting a 3.9% organic decline in quarterly revenue, which amounted to 984 million euros. The stock had then lost nearly 17% in just the session of April 23 and hit a seven-year low of €68.05 on April 30. Over the week, the stock has risen by 4.1%.
As a reminder, the Institut Mérieux, a reference shareholder, strengthened its position in the capital at the beginning of May.
The Stock Remains Far from Its Moving Averages
The price is still well below its moving averages. The MM20 is at €78.87, which is 6.62% above the current price. The gap is more pronounced compared to the MM200, which is at €104.98 (nearly 30% above). The RSI at 31 has just exited the oversold zone, a configuration consistent with the technical rebound observed after the April 30 low.
The identified support threshold is at €68.25, close to the seven-year low recorded at the end of April. The theoretical resistance is significantly higher, at €93.65. The Bollinger Bands frame the price between €58.87 and €98.87, with the stock operating in the lower part of the band (37%).
The next key date on the financial calendar is the publication of the first half 2026 results, expected on July 28, 2026. The third quarter revenue will follow on November 8, 2026.
